
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.4 20241031//EN" "JATS-archivearticle1-4-mathml3.dtd">
<article article-type="case-report" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Surg Oncol</journal-id><journal-id journal-id-type="iso-abbrev">World J Surg Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">199</journal-id><journal-id journal-id-type="pmc-domain">wjsurgonc</journal-id><journal-id journal-id-type="nlm-id">101170544</journal-id><journal-title-group><journal-title>World Journal of Surgical Oncology</journal-title></journal-title-group><issn pub-type="epub">1477-7819</issn><?publisher_abbrev csg?><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9976409</article-id><article-id pub-id-type="pmcid-ver">PMC9976409.1</article-id><article-id pub-id-type="pmcaid">9976409</article-id><article-id pub-id-type="pmcaiid">9976409</article-id><article-id pub-id-type="pmid">36855132</article-id><article-id pub-id-type="doi">10.1186/s12957-023-02934-w</article-id><article-id pub-id-type="publisher-id">2934</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Inflammatory myofibroblastic tumour of the common bile duct: a case report and literature review</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="X">Xiang</given-names></name><address><email>603186363@qq.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="G">Guoli</given-names></name><address><email>924761585@qq.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="J">Jinjing</given-names></name><address><email>jinjingwangls@163.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zheng</surname><given-names initials="H">Hong</given-names></name><address><email>zhenghonghq@hotmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.413390.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 6938</institution-id><institution>Department of Pathology, </institution><institution>The Affiliated Hospital of Zunyi Medical University, </institution></institution-wrap>Zunyi City, Guizhou Province People’s Republic of China </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>21</volume><issue-id pub-id-type="pmc-issue-id">424968</issue-id><elocation-id>69</elocation-id><history><date date-type="received"><day>6</day><month>12</month><year>2022</year></date><date date-type="accepted"><day>11</day><month>2</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>02</day><month>03</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-03-02 04:10:11.480"><day>02</day><month>03</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>© The Author(s) 2023</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12957_2023_Article_2934.pdf"><?pdf-name 12957_2023_Article_2934.pdf?><?pdf-size 1572968?><?pdf-md5 288adbcbf05a3588f2bdfce36c38cf1e?><?pdf-image-server-status NEVER_LOAD?><?pdf-cloudpmc-urn urn:app:97a9/9976409/288adbcbf05a/12957_2023_Article_2934.pdf?></self-uri><abstract id="Abs1"><sec><title>Introduction</title><p id="Par1">Inflammatory myofibroblastic tumour (IMT) of the common bile duct (CBD) is an extremely rare low-grade malignancy with various biological behaviours and a lack of specific clinical and histopathological features. Preoperative and intraoperative diagnosis are challenging, and a diagnostic delay may increase surgical complexity.</p></sec><sec><title>Case presentation</title><p id="Par2">We present the case of a 34-year-old male with no relevant medical history who presented with jaundice of 20 days of evolution. Histology and immunohistochemistry confirmed the diagnosis of an IMT with anaplastic lymphoma kinase (ALK)-1 expression. In addition, a review of the relevant literature revealed 13 published reports of biliary IMTs. The clinical history and histopathological features in these 13 cases were compared with those in our case to provide a comprehensive overview of the clinical manifestations and histopathological features of the disease.</p></sec><sec><title>Conclusion</title><p id="Par3">IMT of the CBD is an extremely rare low-grade malignancy that mainly occurs in middle-aged female patients. The main clinical manifestation is monosymptomatic jaundice. The reported tumours originated in the middle and lower segments of the CBD, with an average size of approximately 3.5 cm × 3.0 cm and tumour cells expressing smooth muscle actin (SMA), vimentin and ALK. Abnormal ALK expression and ALK gene rearrangement represent potential histopathological and differential diagnoses. A clear diagnosis by preoperative biopsy and intraoperative frozen section examination is critical and can significantly reduce surgical trauma. The prognosis is good, and very few patients experience recurrence or distant metastasis.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Inflammatory myofibroblastic tumour</kwd><kwd>Common bile duct</kwd><kwd>Clinical</kwd><kwd>Pathology</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par21">Inflammatory myofibroblastic tumours have been reported in various organs, such as the liver, intestine, spleen, kidneys, bladder, lungs, peritoneum and heart, and are most common in the lungs [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. However, an IMT in the common bile duct (CBD) is extremely rare. Only 13 reports of biliary IMTs have been published [<xref ref-type="bibr" rid="CR3">3</xref>]. The disease lacks specific clinical manifestations and immune indicators, and approximately 50% of patients with IMTs have abnormal anaplastic lymphoma kinase (ALK) expression and ALK gene rearrangement [<xref ref-type="bibr" rid="CR4">4</xref>]. The present study reports a case of IMT of the CBD positive for ALK rearrangement and reviews relevant literature to provide a comprehensive overview of the clinical manifestations and histopathological characteristics of the disease to deepen the understanding of the disease and improve preoperative and intraoperative diagnostic rates.</p></sec><sec id="Sec2"><title>Case presentation</title><p id="Par22">We present the case of a 34-year-old male with no relevant medical history who presented with jaundice of 20 days of evolution. His examination revealed scleral and whole-body skin icterus. There was no abdominal tenderness, rebound tenderness, and the Murphy test was negative, with no palpable mass. There was no evidence of any other organomegaly or lymphadenopathy. His test results on admission were as follows: total bilirubin, 5.17mg/dl; direct bilirubin, 2.49 mg/dl; alkaline phosphatase, 152 U/L; and CA199, 58.5 U/ml. Viral serological tests for hepatitis A, B and C and HIV were negative. Computed tomography (CT) revealed the following: soft tissue nodules in the CBD with clear borders, inhomogeneous morphology, heterogeneous density, equal or slightly low-density changes and nodules bulging into the lumen of the CBD. In the venous phase, there was significant heterogeneous enhancement, which was more obvious than that in the arterial phase and showed gradual strengthening changes (Fig. <xref rid="Fig1" ref-type="fig">1</xref>a–c). Magnetic resonance cholangiopancreatography revealed a localized filling defect in the lower part of the CBD with luminal narrowing (Fig. <xref rid="Fig1" ref-type="fig">1</xref>d). The patient was evaluated by a multidisciplinary committee. The clinical diagnosis was obstructive jaundice with the possibility of bile duct cancer. Laparoscopic pancreaticoduodenectomy was performed. Intraoperatively, adhesions of the omentum and abdominal wall were observed, no ascites were observed in the abdominal cavity and severe cholestasis was observed in the liver. A mass approximately 1.5 × 1.5 cm in size was detected in the lower segment of the CBD. The gallbladder, duodenum, part of the stomach, CBD and head of the pancreas were removed. The bile duct and jejunum were anastomosed, the jejunum and pancreas were anastomosed and a silicone stent and drainage tube were placed. No biopsy was taken during the operation, and there was no biliary leakage.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p><bold>a</bold> Axial pre-contrast CT image. <bold>b</bold> axial post-contrast CT image in arterial phase. <bold>c</bold> Axial post-contrast CT image in portal venous image in delayed phase shows a heterogeneously enhancing mass at common bile duct (CBD) [red arrow in (<bold>c</bold>)]. <bold>d</bold> MRI image shows diffuse dilatation of the intrahepatic biliary radicles and proximal common bile duct (CBD) with narrowing noted at the middle of the CBD</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="12957_2023_2934_Fig1_HTML.jpg"><?image-name 12957_2023_2934_Fig1_HTML.jpg?><?image-size 130447?><?image-md5 19da3253f876d59bc4dbf1f82e0d3e81?><?image-image-server-status LOAD_COMPLETED?><?image-original-height 1274?><?image-original-width 1180?><?image-scaled-height 849?><?image-scaled-width 786?><?image-cloudpmc-urn urn:cdn:blobs/97a9/9976409/19da3253f876/12957_2023_2934_Fig1_HTML.jpg?><?thumb-name 12957_2023_2934_Fig1_HTML.gif?><?thumb-size 4514?><?thumb-md5 f3683847ee4cc1051c36d67d008c923a?><?thumb-image-server-status NEVER_LOAD?><?thumb-scaled-height 108?><?thumb-scaled-width 100?><?thumb-cloudpmc-urn urn:cdn:blobs/97a9/9976409/f3683847ee4c/12957_2023_2934_Fig1_HTML.gif?></graphic></fig></p><p id="Par23">Pathological examination revealed a large 2 cm × 2 cm solid nodule at the CBD with a grey–yellow colour and an unclear surrounding border. Microscope showed that the myofibroblast spindle cells were tightly packed, with extensive infiltration of chronic inflammatory cells, slightly heterogeneous tumour cells and most regional nucleuses &lt; 5/10 high-power fields (HPF) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>a–b). No tumour involvement was observed in the duodenal ends, gastric segments, CBD ends or pancreatic margins. Furthermore, immunohistochemical analysis showed positivity for vimentin (Fig. <xref rid="Fig3" ref-type="fig">3</xref>a), ALK (Fig. <xref rid="Fig3" ref-type="fig">3</xref>b) and SMA (Fig. <xref rid="Fig3" ref-type="fig">3</xref>c). However, results for desmin, cytokeratin 7 (CK7), S-100, Dog-1 (Fig. <xref rid="Fig3" ref-type="fig">3</xref>d), cluster of differentiation 117 (CD117), cluster of differentiation 34 (CD34), succinate dehydrogenase (SDH) and cytokeratin (CK) expression were negative. The Ki-67 proliferative index was approximately &lt; 20%, and the IgG4/IgG ratio was &lt; 30%. Immunofluorescence in situ hybridization (FISH) indicated that ALK was represented by a mainly orange-green signal or only an orange signal, indicating positive results (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). The postoperative pathological diagnosis was IMT. The patient was followed up for 3 years, and he is currently asymptomatic and without recurrence.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p><bold>a</bold> Spindle-shaped cells arranged in fascicles in a background of chronic inflammatory cells (H&amp;E 100×). <bold>b</bold> Spindle-shaped cells in a background of chronic inflammatory cells (H&amp;E 400×)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="12957_2023_2934_Fig2_HTML.jpg"><?image-name 12957_2023_2934_Fig2_HTML.jpg?><?image-size 190079?><?image-md5 3d44003b938765bdd87594a5b5d74a9b?><?image-image-server-status LOAD_COMPLETED?><?image-original-height 651?><?image-original-width 1416?><?image-scaled-height 326?><?image-scaled-width 708?><?image-cloudpmc-urn urn:cdn:blobs/97a9/9976409/3d44003b9387/12957_2023_2934_Fig2_HTML.jpg?><?thumb-name 12957_2023_2934_Fig2_HTML.gif?><?thumb-size 14180?><?thumb-md5 e201429c04649d1ab00ef62d7c894371?><?thumb-image-server-status NEVER_LOAD?><?thumb-scaled-height 80?><?thumb-scaled-width 174?><?thumb-cloudpmc-urn urn:cdn:blobs/97a9/9976409/e201429c0464/12957_2023_2934_Fig2_HTML.gif?></graphic></fig><fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p><bold>a</bold> Positive staining with vimentin (100×). <bold>b</bold> Positive staining with ALK (100×). <bold>c</bold> Positive staining with SMA (100×). <bold>d</bold> Negative staining with Dog-1 (100×)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="12957_2023_2934_Fig3_HTML.jpg"><?image-name 12957_2023_2934_Fig3_HTML.jpg?><?image-size 331847?><?image-md5 16f8ebc8f8fa84d7c0ef5504ad1a967f?><?image-image-server-status LOAD_COMPLETED?><?image-original-height 1326?><?image-original-width 1416?><?image-scaled-height 663?><?image-scaled-width 708?><?image-cloudpmc-urn urn:cdn:blobs/97a9/9976409/16f8ebc8f8fa/12957_2023_2934_Fig3_HTML.jpg?><?thumb-name 12957_2023_2934_Fig3_HTML.gif?><?thumb-size 10348?><?thumb-md5 7406556d98f35c59f0796dcf96629874?><?thumb-image-server-status NEVER_LOAD?><?thumb-scaled-height 94?><?thumb-scaled-width 100?><?thumb-cloudpmc-urn urn:cdn:blobs/97a9/9976409/7406556d98f3/12957_2023_2934_Fig3_HTML.gif?></graphic></fig><fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Immunofluorescence in situ hybridization (FISH) indicated that ALK was represented by a mainly orange-green signal or only an orange signal, indicating positive results</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="12957_2023_2934_Fig4_HTML.jpg"><?image-name 12957_2023_2934_Fig4_HTML.jpg?><?image-size 55225?><?image-md5 60d38e24854ec7da5f571ad96e851eee?><?image-image-server-status LOAD_COMPLETED?><?image-original-height 812?><?image-original-width 1180?><?image-scaled-height 541?><?image-scaled-width 786?><?image-cloudpmc-urn urn:cdn:blobs/97a9/9976409/60d38e24854e/12957_2023_2934_Fig4_HTML.jpg?><?thumb-name 12957_2023_2934_Fig4_HTML.gif?><?thumb-size 4465?><?thumb-md5 131df4f3cebc190160af56a285a2f6d0?><?thumb-image-server-status NEVER_LOAD?><?thumb-scaled-height 80?><?thumb-scaled-width 116?><?thumb-cloudpmc-urn urn:cdn:blobs/97a9/9976409/131df4f3cebc/12957_2023_2934_Fig4_HTML.gif?></graphic></fig></p></sec><sec id="Sec3"><title>Discussion</title><p id="Par24">IMT was once regarded as a benign reactive tumour-like hyperplasia with spindle fibroblasts and myofibroblasts undergoing hyperplasia, accompanied by fibroblast infiltration as the main pathological feature [<xref ref-type="bibr" rid="CR5">5</xref>]. Tumours of this pathologic morphology were first identified in the CBD by Haith et al. [<xref ref-type="bibr" rid="CR6">6</xref>] in 1964 and first described in detail in the lungs by Bahadori et al. [<xref ref-type="bibr" rid="CR7">7</xref>] in 1973; IMTs were subsequently reported in various organs [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Due to histological particularities, these tumours have had many different names in the literature, such as inflammatory pseudotumours, plasma cell granulomas and plasma cell pseudotumours. With deeper understanding and research, the World Health Organization (WHO) (2002) eventually classified these soft tissue tumours as IMTs, namely, borderline tumours with occasional metastasis [<xref ref-type="bibr" rid="CR10">10</xref>]. IMTs in the CBD are extremely rare, with only 13 previously reported cases in addition to our present case (Table <xref rid="Tab1" ref-type="table">1</xref>). IMTs seem to be more common in middle-aged women; the male-to-female ratio is 2:5, and the age range of IMT patients is 6 to 71 years (average, 46.5 years). The main clinical manifestations are jaundice without other associated symptoms, but a few patients also show abdominal pain, emaciation and fever [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Biliary bleeding rarely occurs [<xref ref-type="bibr" rid="CR17">17</xref>]. The patient in the present case was a 34-year-old male with jaundice as the predominant clinical manifestation, similar to the 13 previously reported cases. The levels of tumour markers are usually normal; however, our patient had a slightly elevated CA199 level. CA199 may be an effective tumour marker for the diagnosis of cholangiocarcinoma and monitoring the efficacy of treatment [<xref ref-type="bibr" rid="CR22">22</xref>]. Therefore, cholangiocarcinoma should be considered as the primary differential diagnosis before surgery. Compared with the 13 previously reported cases, the reason for the elevated CA199 level in this case was unclear; however, due to the small number of reported IMT cases at present, the possibility of CA199 being related to IMT of the CBD cannot be excluded. Liver function examination revealed an elevated bilirubin level but normal or only slightly abnormal ALT and AST levels. ALT and AST levels were significantly abnormal in only one patient, reported by Fukushima et al. [<xref ref-type="bibr" rid="CR13">13</xref>]. However, the bilirubin level was also elevated in the present case. In relation to the radiological findings of this entity, a common, narrow CBD is usually observed, but distinguishing it from cholangiocarcinoma is not possible; additionally, preoperative diagnosis is difficult. The patient in the present case also showed a CBD mass with stricture on imaging. Surgery remains the preferred treatment regimen. Interestingly, Lopez-Tomassetti et al. [<xref ref-type="bibr" rid="CR18">18</xref>] reported local recurrence 4 years after choledochal IMT resection but chose corticosteroid treatment; complete tumour remission was reported 3 months after treatment, and 6 months after continued dose maintenance therapy, the patients remained well, with liver function markers in the normal range. This treatment approach represents a feasible secondary option for patients clinically unable to undergo surgery. Of the patient’s follow-up, the duration of follow-up ranged from 6 weeks to 19 years, and three have been reported to have experienced recurrence and distant metastases [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Our patient was followed up for 3 years, and he is currently asymptomatic and without recurrence. Walsh et al. [<xref ref-type="bibr" rid="CR14">14</xref>] reported a 19-year follow-up of a patient who exhibited distant metastases occurring mainly in the lungs [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR23">23</xref>], which is also the most common primary site of IMTs. Therefore, IMTs of the CBD are capable of recurrence and distant metastasis. Given the rarity of these tumours, long-term follow-up of patients with IMTs of the CBD is scarcely reported in the literature. Extrabiliary IMTs have the potential for local infiltration, recurrence and persistent local growth. Local recurrence may occur after many years; thus, strict follow-up after surgery is required [<xref ref-type="bibr" rid="CR24">24</xref>]. In many cases, the behaviour of these tumours is complex and difficult to predict, especially when they occur at sites with few corresponding case reports in the literature. Although IMTs are known to be prone to local recurrence and may develop metastases, there are documented cases of both biliary and extrabiliary IMT patients without disease recurrence over prolonged follow-up periods. Arredondo Montero J. et al. [<xref ref-type="bibr" rid="CR25">25</xref>] reported a case of a 2-month-old girl presenting with an ileal IMT. Long-term follow-up revealed that the patient remained asymptomatic and without recurrence after 15 years.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>IMTs in the CBD have been previously reported cases in addition to present case</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Authors/publication year</th><th colspan="1" rowspan="1">Age/sex</th><th colspan="1" rowspan="1">Symptoms</th><th colspan="1" rowspan="1">Tumour marker</th><th colspan="1" rowspan="1">Liver function test</th><th colspan="1" rowspan="1">Location</th><th colspan="1" rowspan="1">Size (cm)</th><th colspan="1" rowspan="1">Immunohistochemistry</th><th colspan="1" rowspan="1">Treatment</th><th colspan="1" rowspan="1">Follow-up/outcome</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">E. E. Haith et al. [<xref ref-type="bibr" rid="CR6">6</xref>] (1964)</td><td colspan="1" rowspan="1">6/M</td><td colspan="1" rowspan="1">Jaundice</td><td colspan="1" rowspan="1">─</td><td colspan="1" rowspan="1">─</td><td colspan="1" rowspan="1">Distal CBD</td><td colspan="1" rowspan="1">─</td><td colspan="1" rowspan="1">─</td><td colspan="1" rowspan="1">EHBD excision</td><td colspan="1" rowspan="1">5 months/NR</td></tr><tr><td colspan="1" rowspan="1">J. D. Stamatakis et al. [<xref ref-type="bibr" rid="CR11">11</xref>] (1979)</td><td colspan="1" rowspan="1">13/F</td><td colspan="1" rowspan="1">Jaundice, abdominal pain</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">TB: 13.4 mg/dL</td><td colspan="1" rowspan="1">CBD, CD, CHD</td><td colspan="1" rowspan="1">3 cm × 3 cm</td><td colspan="1" rowspan="1">─</td><td colspan="1" rowspan="1">PD &amp; celecoxib</td><td colspan="1" rowspan="1">21 months/NR</td></tr><tr><td colspan="1" rowspan="1">H. Ikeda et al. [<xref ref-type="bibr" rid="CR12">12</xref>] (1990)</td><td colspan="1" rowspan="1">43/F</td><td colspan="1" rowspan="1">Fever, jaundice, significant weight loss</td><td colspan="1" rowspan="1">─</td><td colspan="1" rowspan="1">─</td><td colspan="1" rowspan="1">CHD, ProxCBD</td><td colspan="1" rowspan="1">─</td><td colspan="1" rowspan="1">─</td><td colspan="1" rowspan="1">Surgery</td><td colspan="1" rowspan="1">7 months/lung mets.</td></tr><tr><td colspan="1" rowspan="1">N. Fukushima et al. [<xref ref-type="bibr" rid="CR13">13</xref>] (1997)</td><td colspan="1" rowspan="1">58/F</td><td colspan="1" rowspan="1">Abnormal liver function on physical examination</td><td colspan="1" rowspan="1">Normal</td><td colspan="1" rowspan="1">TB: 0.7 mg/dl, AST: 159 U/l, ALT: 454 U/l</td><td colspan="1" rowspan="1">Mid-lower CBD</td><td colspan="1" rowspan="1">2 cm × 2 cm</td><td colspan="1" rowspan="1">Vimentin (+), desmin (−), muscle-specific actin (−) and CD34 (+)</td><td colspan="1" rowspan="1">PD surgery</td><td colspan="1" rowspan="1">Not mentioned</td></tr><tr><td colspan="1" rowspan="1">S. V. Walsh et al. [<xref ref-type="bibr" rid="CR14">14</xref>] (1998)</td><td colspan="1" rowspan="1">50/M</td><td colspan="1" rowspan="1">─</td><td colspan="1" rowspan="1">─</td><td colspan="1" rowspan="1">─</td><td colspan="1" rowspan="1">Proximal CBD</td><td colspan="1" rowspan="1">─</td><td colspan="1" rowspan="1">─</td><td colspan="1" rowspan="1">PD</td><td colspan="1" rowspan="1">19 years/metastasis</td></tr><tr><td colspan="1" rowspan="1">R. Sobesky et al. [<xref ref-type="bibr" rid="CR15">15</xref>] (2003)</td><td colspan="1" rowspan="1">51/F</td><td colspan="1" rowspan="1">Jaundice</td><td colspan="1" rowspan="1">Normal</td><td colspan="1" rowspan="1">TB: 20.8mg/dL</td><td colspan="1" rowspan="1">Distal CBD</td><td colspan="1" rowspan="1">1.5 cm</td><td colspan="1" rowspan="1">CD34 (+), desmin (+), S-100 (+), SMA+</td><td colspan="1" rowspan="1">PD</td><td colspan="1" rowspan="1">2 years/NR</td></tr><tr><td colspan="1" rowspan="1">Antonio Martín Malagón et al. [<xref ref-type="bibr" rid="CR16">16</xref>] (2006)</td><td colspan="1" rowspan="1">51/F</td><td colspan="1" rowspan="1">Jaundice</td><td colspan="1" rowspan="1">Normal</td><td colspan="1" rowspan="1">TB/DB: 11.3/9.3 mg/dl</td><td colspan="1" rowspan="1">Distal CBD</td><td colspan="1" rowspan="1">0.7 cm × 0.7 cm</td><td colspan="1" rowspan="1">SMA (+), S100 (−), vimentin (+), CD45 (+), CD68 (+)</td><td colspan="1" rowspan="1">PD</td><td colspan="1" rowspan="1">1 year/NR</td></tr><tr><td colspan="1" rowspan="1">Anuradha Sekaran et al. [<xref ref-type="bibr" rid="CR17">17</xref>] (2006)</td><td colspan="1" rowspan="1">17/F</td><td colspan="1" rowspan="1">Jaundice, abdominal pain, black stool</td><td colspan="1" rowspan="1">─</td><td colspan="1" rowspan="1">TB/DB: 3.9/2.3 mg/dL</td><td colspan="1" rowspan="1">Distal CBD</td><td colspan="1" rowspan="1">─</td><td colspan="1" rowspan="1">SMA (+), S100 (+), vimentin (+)</td><td colspan="1" rowspan="1">PD</td><td colspan="1" rowspan="1">6 weeks/NR</td></tr><tr><td colspan="1" rowspan="1"><p>E M López-Tomassetti</p><p>Fernández et al. [<xref ref-type="bibr" rid="CR18">18</xref>] (2006)</p></td><td colspan="1" rowspan="1">55/F</td><td colspan="1" rowspan="1">Jaundice</td><td colspan="1" rowspan="1">─</td><td colspan="1" rowspan="1">─</td><td colspan="1" rowspan="1">Distal CBD</td><td colspan="1" rowspan="1">5 cm × 5 cm</td><td colspan="1" rowspan="1">─</td><td colspan="1" rowspan="1">Cortical steroid therapy</td><td colspan="1" rowspan="1">3 months/tumor regression</td></tr><tr><td colspan="1" rowspan="1">Bassam Abu-Wasel et al. [<xref ref-type="bibr" rid="CR19">19</xref>] (2012)</td><td colspan="1" rowspan="1">55/M</td><td colspan="1" rowspan="1">Jaundice</td><td colspan="1" rowspan="1">Normal</td><td colspan="1" rowspan="1">TB: 20.8mg/dL</td><td colspan="1" rowspan="1">Distal CBD</td><td colspan="1" rowspan="1">3 cm × 3 cm</td><td colspan="1" rowspan="1">─</td><td colspan="1" rowspan="1">PD</td><td colspan="1" rowspan="1">14 months/NR</td></tr><tr><td colspan="1" rowspan="1">K. Vasiliadis et al. [<xref ref-type="bibr" rid="CR20">20</xref>] (2013)</td><td colspan="1" rowspan="1">70/F</td><td colspan="1" rowspan="1">Jaundice</td><td colspan="1" rowspan="1">Normal</td><td colspan="1" rowspan="1">DB: 14.9 mg/dl</td><td colspan="1" rowspan="1">Mid-distal CBD</td><td colspan="1" rowspan="1">3 cm × 3 cm</td><td colspan="1" rowspan="1">─</td><td colspan="1" rowspan="1">PD</td><td colspan="1" rowspan="1">8 months/NR</td></tr><tr><td colspan="1" rowspan="1">Aureen D’Cunha et al. [<xref ref-type="bibr" rid="CR21">21</xref>] (2016)</td><td colspan="1" rowspan="1">12/F</td><td colspan="1" rowspan="1">Jaundice, abdominal pain</td><td colspan="1" rowspan="1">─</td><td colspan="1" rowspan="1">TB/DB: 13.86 /12.1 mg/dL</td><td colspan="1" rowspan="1">Distal CBD</td><td colspan="1" rowspan="1">4 cm × 4 cm</td><td colspan="1" rowspan="1">SMA (+), ALK (+)</td><td colspan="1" rowspan="1">PD</td><td colspan="1" rowspan="1">9 months/NR</td></tr><tr><td colspan="1" rowspan="1">Ritu Verma et al. [<xref ref-type="bibr" rid="CR3">3</xref>] (2019)</td><td colspan="1" rowspan="1">24/F</td><td colspan="1" rowspan="1">Jaundice</td><td colspan="1" rowspan="1">Normal</td><td colspan="1" rowspan="1">TB/DB: 5.8/2.9 mg/dL</td><td colspan="1" rowspan="1">Mid CBD</td><td colspan="1" rowspan="1">10 cm × 6 cm</td><td colspan="1" rowspan="1">Desmin (+), SMA+, (CK), CD34 (−), CD117 (−), DOG1 (−), ALK1 (−)</td><td colspan="1" rowspan="1">PD</td><td colspan="1" rowspan="1">Not mentioned</td></tr><tr><td colspan="1" rowspan="1">Present case</td><td colspan="1" rowspan="1">34/M</td><td colspan="1" rowspan="1">Jaundice</td><td colspan="1" rowspan="1">CA199: 58.5 U/ml</td><td colspan="1" rowspan="1">TB/DB: 5.17/2.49 mg/dL</td><td colspan="1" rowspan="1">Mid CBD</td><td colspan="1" rowspan="1">2 cm × 2 cm</td><td colspan="1" rowspan="1">Vimentin (+), ALK (+), SMA (+), desmin (−), CK7 (−), S-100 (−), CD34 (−), DOG1 (−), CD117 (−), Ki-67 (20%+)</td><td colspan="1" rowspan="1">PD</td><td colspan="1" rowspan="1">3 years/NR</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">M</italic> male, <italic toggle="yes">F</italic> female, <italic toggle="yes">CBD</italic> common bile duct, <italic toggle="yes">PD</italic> pancreatoduodenectomy, <italic toggle="yes">CD</italic> cystic duct, <italic toggle="yes">CHD</italic> common hepatic duct, <italic toggle="yes">EHBD</italic> extrahepatic bile duct, <italic toggle="yes">TB</italic> total bilirubin, <italic toggle="yes">DB</italic> direct bilirubin, <italic toggle="yes">NR</italic> no recurrence</p></table-wrap-foot></table-wrap></p><p id="Par25">Analysis of tumour pathological characteristics revealed the following: the reported tumours originated in the middle and lower segments of the CBD with an average size of approximately 3.5 cm × 3.0 cm, and the largest tumour, reported by Verma et al., was approximately 10 cm × 6 cm in size [<xref ref-type="bibr" rid="CR3">3</xref>]. Gross lesions are greyish-white, greyish-yellow, firm and nodular. A small number of the lesions are mucoid [<xref ref-type="bibr" rid="CR13">13</xref>]. On histomorphology, three types of IMT growth patterns are observed: (1) the mucus-type pattern, (2) the cellular compact spindle cell pattern, and (3) the fibre-type pattern. The dense spindle cell pattern is the most common, and the different histopathological morphologies are not associated with prognosis, which is consistent with the findings reported by Coffifi et al. [<xref ref-type="bibr" rid="CR8">8</xref>]. The tumour cells express SMA and vimentin; partially express desmin, CD34, CD68 and ALK; and do not express CK or S100. Abnormal ALK expression and ALK gene rearrangement represent histopathological and differential diagnosis, and ALK rearrangement is seen in approximately 50% of patients [<xref ref-type="bibr" rid="CR2">2</xref>]. ALK is a tyrosine kinase receptor, and ALK expression plays an important role in gene rearrangement in the development of IMT [<xref ref-type="bibr" rid="CR26">26</xref>]. In the present case, the tumour occurred in the middle part of the CBD, and the tumour cell growth pattern was mainly of the dense spindle cell type. The immunohistochemical expression pattern in this case is consistent with that in the previously reported case with ALK rearrangement.</p><p id="Par26">Differential diagnosis of IMT of the CBD includes cholangiocarcinoma, gastrointestinal stromal tumour (GIST), leiomyoma and fibromatosis [<xref ref-type="bibr" rid="CR3">3</xref>]. (1) Extrahepatic cholangiocarcinoma occurs predominantly in elderly individuals and often presents with systemic manifestations of malignancy. Immunohistochemistry can assist in identification. (2) GIST usually involves the ampullary/periampullary region. These cells are typically positive for vimentin and SMA but negative for CD117 and DOG1. (3) The boundaries of leiomyomas are clear, and these tumour cells present a rich eosinophilic fibrous cytoplasm and smooth muscle tumour cells that are regularly arranged, woven and have no obvious inflammatory cell infiltration. Immunohistochemistry can assist in identification. (4) IgG4-related sclerosing inflammatory lesions are reported in most cases of IMT of the distal CBD and show a strong association with sclerosing lymphoplasmacytic pancreatitis or autoimmune pancreatitis. In our case, interstitial plasma cells had an IgG4/IgG &lt; 30%. (5) In fibromatosis, more myofibroblasts are seen in the lesions, but the cells are mainly arranged in parallel broad bundles with slightly wavy curves. Obvious infiltration of the surrounding skeletal muscle, tendon and tendon membrane is observed. Inflammatory cell infiltration is not as diffuse as that in IMT; fibromatosis is also associated with CD34 positivity and catenin negativity and no expression of SMA or MSA.</p><p id="Par27">All patients were subsequently diagnosed with infiltrating biliary or peribiliary pseudotumours on laparotomy. No patient was, in fact, thought to have a nonneoplastic lesion before biliary diversion. Extrahepatic biliary resection was performed in 14 patients. However, the final pathological diagnosis was IMT. IMTs of CBD are rare lesions that are often mistaken for aggressive malignancies, and although their appearance is nonspecific, a diagnosis may be made by imaging-directed core biopsy. If biopsy is performed preoperatively or intraoperatively, the trauma of surgery can be reduced.</p></sec><sec id="Sec4"><title>Conclusion</title><p id="Par28">Compared to GIST, leiomyoma and fibromatosis, IMT is considered a less malignant mesenchymal tumour occurring predominantly in children or adolescents or, in the case of IMT of the CBD, in middle-aged female patients. IMT of the CBD is characterized by monosymptomatic jaundice and a tumour in the middle or lower segment of the CBD, with an average size of approximately 3.5 cm × 3.0 cm and diverse histological features. The notable immunohistochemical characteristics of these tumours are SMA expression and partial expression of desmin, vimentin and ALK. Surgical excision is currently considered the treatment of choice for IMT. However, there is some evidence of the effectiveness of corticosteroid therapy. Although IMT of the CBD might be considered in the differential diagnosis of an obstructing extrahepatic biliary lesion, there are no distinctive clinical or imaging features that allow it to be differentiated from cholangiocarcinoma before laparotomy. Awareness of this rare but benign entity, however, might prompt a more limited operative approach when intraoperative resection margins of palpable disease are repeatedly negative for tumour cells. A clear diagnosis by preoperative biopsy and intraoperative frozen section examination is critical and can significantly reduce surgical trauma. The prognosis is good, and very few patients experience recurrence or distant metastasis.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CT</term><def><p id="Par4">Computed tomography</p></def></def-item><def-item><term>MRI</term><def><p id="Par5">Magnetic resonance imaging</p></def></def-item><def-item><term>CBD</term><def><p id="Par6">Common bile duct</p></def></def-item><def-item><term>M</term><def><p id="Par7">Male</p></def></def-item><def-item><term>F</term><def><p id="Par8">Female</p></def></def-item><def-item><term>PD</term><def><p id="Par9">Pancreatoduodenectomy</p></def></def-item><def-item><term>NR</term><def><p id="Par10">No recurrence</p></def></def-item><def-item><term>CD</term><def><p id="Par11">Cystic duct</p></def></def-item><def-item><term>CHD</term><def><p id="Par12">Common hepatic duct</p></def></def-item><def-item><term>EHBD</term><def><p id="Par13">Extrahepatic bile duct</p></def></def-item><def-item><term>ALK</term><def><p id="Par14">Anaplastic lymphoma kinase</p></def></def-item><def-item><term>SMA</term><def><p id="Par15">Smooth muscle actin</p></def></def-item><def-item><term>CK</term><def><p id="Par16">Cytokeratin</p></def></def-item><def-item><term>CK7</term><def><p id="Par17">Cytokeratin 7</p></def></def-item><def-item><term>SDH</term><def><p id="Par18">Succinate dehydrogenase</p></def></def-item><def-item><term>CD34</term><def><p id="Par19">Cluster of differentiation 34</p></def></def-item><def-item><term>CD117</term><def><p id="Par20">Cluster of differentiation 117</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher’s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors would like to thank AJE (American Journal Experts) for English language editing.</p></ack><notes notes-type="author-contribution"><title>Authors’ contributions</title><p>XH wrote the main manuscript. LGL prepared Figs <xref rid="Fig1" ref-type="fig">1</xref>, <xref rid="Fig2" ref-type="fig">2</xref>, <xref rid="Fig3" ref-type="fig">3</xref>, <xref rid="Fig4" ref-type="fig">4</xref> and Table <xref rid="Tab1" ref-type="table">1</xref>.  JJW revised the final manuscript. All the authors have read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>None.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>All the data regarding the findings are available within the manuscript.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par29">This case report was approved by the Ethics Committee of the Affiliated Hospital of Zunyi Medical University. Written informed consent was obtained from the patient for publication of this clinical case report.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par30">Written informed consent was obtained from the patient for publication of this case report and any accompanying images.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par31">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agrons</surname><given-names>GA</given-names></name><name name-style="western"><surname>Rosado-de-Christenson</surname><given-names>ML</given-names></name><name name-style="western"><surname>Kirejczyk</surname><given-names>WM</given-names></name><etal/></person-group><article-title>Pulmonary inflammatory pseudotumor: radiologic features</article-title><source>Radiology</source><year>1998</year><volume>206</volume><issue>2</issue><fpage>511</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1148/radiology.206.2.9457206</pub-id><pub-id pub-id-type="pmid">9457206</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Coffin CM, Fletcher JA. Inflammatory myofibroblastic tumor. In: Fletcher CDM, Bridge JA, Hogendooorn PCW, Mertern F, editors. WHO classification of tumors of soft tissue and bone. 4th edition. IARC. Lyon; 2013.</mixed-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verma</surname><given-names>R</given-names></name><name name-style="western"><surname>Saha</surname><given-names>A</given-names></name><name name-style="western"><surname>Saha</surname><given-names>K</given-names></name></person-group><article-title>Inflammatory myofibroblastic tumor of the mid common bile duct masquerading as cholangiocarcinoma</article-title><source>J Gastrointest Cancer.</source><year>2019</year><volume>50</volume><issue>3</issue><fpage>613</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1007/s12029-018-0074-7</pub-id><pub-id pub-id-type="pmid">29453762</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antonescu</surname><given-names>CR</given-names></name><name name-style="western"><surname>Suurmeijer</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1genefusions and rare novel RET rearrangement</article-title><source>Am J Surg Pathol.</source><year>2015</year><volume>39</volume><issue>7</issue><fpage>957</fpage><lpage>967</lpage><pub-id pub-id-type="doi">10.1097/PAS.0000000000000404</pub-id><pub-id pub-id-type="pmid">25723109</pub-id><pub-id pub-id-type="pmcid">PMC4465992</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siemion</surname><given-names>K</given-names></name><name name-style="western"><surname>Reszec-Gielazyn</surname><given-names>J</given-names></name><name name-style="western"><surname>Kisluk</surname><given-names>J</given-names></name><etal/></person-group><article-title>What do we know about inflammatory myofibroblastic tumors? - A systematic review</article-title><source>Adv Med Sci.</source><year>2022</year><volume>67</volume><issue>1</issue><fpage>129</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.advms.2022.02.002</pub-id><pub-id pub-id-type="pmid">35219201</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haith</surname><given-names>EE</given-names></name><name name-style="western"><surname>Kepes</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Holder</surname><given-names>TM</given-names></name></person-group><article-title>Inflammatory pseudotumour involving the common bile duct of a six year-old: successful pancreatico-duodenectomy</article-title><source>Surgery</source><year>1964</year><volume>56</volume><fpage>436</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">14213845</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahadori</surname><given-names>M</given-names></name><name name-style="western"><surname>Liebow</surname><given-names>AA</given-names></name></person-group><article-title>Plasma cell granulomas of the lung</article-title><source>Cancer</source><year>1973</year><volume>31</volume><fpage>191</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(197301)31:1&lt;191::AID-CNCR2820310127&gt;3.0.CO;2-D</pub-id><pub-id pub-id-type="pmid">4683037</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Coffifi n CM, Watterson J, Priest JR, Dehner LP. Extrapulmonary inflfl ammatory myofifi broblastic tumor (inflfl ammatory pseudotumor): a clinicopathological and immunohistochemical study of 84 cases. Am J Surg Pathol. 1995;19:859–872.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000478-199508000-00001</pub-id><pub-id pub-id-type="pmid">7611533</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pettinato</surname><given-names>G</given-names></name><name name-style="western"><surname>Manivel</surname><given-names>JC</given-names></name><name name-style="western"><surname>de la Rosa</surname><given-names>N</given-names></name><name name-style="western"><surname>Dehner</surname><given-names>LP</given-names></name></person-group><article-title>Inflfl ammatory myofifi broblastic tumor(plasma cellgranuloma):clinicopathologicstudy of 20 cases with immunohistochemical and ultrastructural observations</article-title><source>Am J ClinPathol</source><year>1990</year><volume>94</volume><fpage>538</fpage><lpage>546</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ajcp/94.5.538</pub-id><pub-id pub-id-type="pmid">2239820</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Letcher</surname><given-names>CDM</given-names></name><name name-style="western"><surname>Unni</surname><given-names>KK</given-names></name><name name-style="western"><surname>Mertens</surname><given-names>F</given-names></name></person-group><source>Pathology and genetics of tumours of soft tissue and bone[M]//World Health Organization classification of tumours</source><year>2002</year><publisher-loc>Lyon</publisher-loc><publisher-name>IARC Press</publisher-name><fpage>48</fpage><lpage>106</lpage></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stamatakis</surname><given-names>JD</given-names></name><name name-style="western"><surname>Howard</surname><given-names>ER</given-names></name><name name-style="western"><surname>Williams</surname><given-names>R</given-names></name></person-group><article-title>Benign inflammatory tumour of the common bile duct</article-title><source>Br J Surg.</source><year>1979</year><volume>66</volume><issue>4</issue><fpage>257</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1002/bjs.1800660412</pub-id><pub-id pub-id-type="pmid">454993</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ikeda</surname><given-names>H</given-names></name><name name-style="western"><surname>Oka</surname><given-names>T</given-names></name><name name-style="western"><surname>Imafuku</surname><given-names>I</given-names></name><etal/></person-group><article-title>A case of inflammatory pseudotumor of the gallbladder and bile duct</article-title><source>The American Journal of Gastroenterology.</source><year>1990</year><volume>85</volume><issue>2</issue><fpage>203</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">2405646</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukushima</surname><given-names>N</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>M</given-names></name><name name-style="western"><surname>Abe</surname><given-names>T</given-names></name><etal/></person-group><article-title>A case of inflammatory pseudotumour of the common bile duct</article-title><source>Virchows Arch.</source><year>1997</year><volume>431</volume><issue>3</issue><fpage>219</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1007/s004280050092</pub-id><pub-id pub-id-type="pmid">9334845</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>SV</given-names></name><name name-style="western"><surname>Evangelista</surname><given-names>F</given-names></name><name name-style="western"><surname>Khettry</surname><given-names>U</given-names></name></person-group><article-title>Inflammatory myofibroblastic tumor of the pancreaticobiliary region: morphologic and immunocytochemical study of three cases</article-title><source>Am J Surg Pathol.</source><year>1998</year><volume>22</volume><issue>4</issue><fpage>412</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1097/00000478-199804000-00004</pub-id><pub-id pub-id-type="pmid">9537467</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sobesky</surname><given-names>R</given-names></name><name name-style="western"><surname>Chollet</surname><given-names>JM</given-names></name><name name-style="western"><surname>Prat</surname><given-names>F</given-names></name><etal/></person-group><article-title>Inflammatory pseudotumor of the common bile duct</article-title><source>Endoscopy.</source><year>2003</year><volume>35</volume><issue>8</issue><fpage>698</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1055/s-2003-41522</pub-id><pub-id pub-id-type="pmid">12929069</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martín Malagón</surname><given-names>A</given-names></name><name name-style="western"><surname>López-Tomassetti Fernández</surname><given-names>E</given-names></name><name name-style="western"><surname>Arteaga González</surname><given-names>I</given-names></name><name name-style="western"><surname>Carrillo Pallarés</surname><given-names>A</given-names></name><name name-style="western"><surname>Díaz</surname><given-names>LH</given-names></name></person-group><article-title>Inflammatory myofibroblastic tumor of the distal bile duct associated with lymphoplasmacytic sclerosing pancreatitis. Case report and review of the literature</article-title><source>Pancreatology.</source><year>2006</year><volume>6</volume><issue>1-2</issue><fpage>145</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1159/000090256</pub-id><pub-id pub-id-type="pmid">16354963</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Sekaran A, Lakhtakia S, Pradeep R, et al. Inflammatory myofibroblastic tumor of biliary tract presenting as recurrent GI bleed(with video). Gastrointest Endosc. 2006;63(7):1077-9.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gie.2006.01.017</pub-id><pub-id pub-id-type="pmid">16733137</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez-Tomassetti Fernandez</surname><given-names>EM</given-names></name><name name-style="western"><surname>Luis</surname><given-names>HD</given-names></name><name name-style="western"><surname>Malagon</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Recurrence of inflammatory pseudotumor in the distal bile duct: lessons learned from a single case and reported cases</article-title><source>World J Gastroenterol.</source><year>2006</year><volume>12</volume><issue>24</issue><fpage>3938</fpage><lpage>3943</lpage><pub-id pub-id-type="doi">10.3748/wjg.v12.i24.3938</pub-id><pub-id pub-id-type="pmid">16804988</pub-id><pub-id pub-id-type="pmcid">PMC4087951</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abu-Wasel</surname><given-names>B</given-names></name><name name-style="western"><surname>Eltawil</surname><given-names>KM</given-names></name><name name-style="western"><surname>Molinari</surname><given-names>M</given-names></name></person-group><article-title>Benign inflammatory pseudotumour mimicking extrahepatic bile duct cholangiocarcinoma in an adult man presenting with painless obstructive jaundice</article-title><source>BMJ Case Rep.</source><year>2012</year><volume>27</volume><issue>2012</issue><fpage>006514</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bcr-2012-006514</pub-id><pub-id pub-id-type="pmcid">PMC4543733</pub-id><pub-id pub-id-type="pmid">22739336</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vasiliadis</surname><given-names>K</given-names></name><name name-style="western"><surname>Fortounis</surname><given-names>K</given-names></name><name name-style="western"><surname>Papavasiliou</surname><given-names>C</given-names></name><etal/></person-group><article-title>Mid common bile duct inflammatory pseudotumor mimicking cholangiocarcinoma. A case report and literature review</article-title><source>Int J Surg Case Rep.</source><year>2014</year><volume>5</volume><issue>1</issue><fpage>12</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.ijscr.2013.10.017</pub-id><pub-id pub-id-type="pmid">24394855</pub-id><pub-id pub-id-type="pmcid">PMC3907201</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D'Cunha</surname><given-names>A</given-names></name><name name-style="western"><surname>Jehangir</surname><given-names>S</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>R</given-names></name></person-group><article-title>Inflammatory myofibroblastic tumor of common bile duct in a girl</article-title><source>APSP J Case Rep.</source><year>2016</year><volume>7</volume><issue>4</issue><fpage>28</fpage><pub-id pub-id-type="doi">10.21699/ajcr.v7i4.445</pub-id><pub-id pub-id-type="pmid">27672578</pub-id><pub-id pub-id-type="pmcid">PMC5027059</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Application of joint detection of AFP, CA19-9, CA125 and CEA in identification and diagnosis of cholangiocarcinoma</article-title><source>Asian Pac J Cancer Prev.</source><year>2015</year><volume>16</volume><issue>8</issue><fpage>3451</fpage><lpage>3455</lpage><pub-id pub-id-type="doi">10.7314/APJCP.2015.16.8.3451</pub-id><pub-id pub-id-type="pmid">25921161</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">WHO Classification of Tumours Editorial Board. WHO classification of tumours. Soft tissue and bone tumours. 5th ed. Lyon: IARC Press, 2020:109-111.</mixed-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Behranwala</surname><given-names>KA</given-names></name><name name-style="western"><surname>Straker</surname><given-names>P</given-names></name><name name-style="western"><surname>Wan</surname><given-names>A</given-names></name><etal/></person-group><article-title>Inflammatory myofibroblastic tumour of the gallbladder</article-title><source>World J Surg Oncol.</source><year>2005</year><volume>3</volume><issue>1</issue><fpage>24</fpage><pub-id pub-id-type="doi">10.1186/1477-7819-3-24</pub-id><pub-id pub-id-type="pmid">15862123</pub-id><pub-id pub-id-type="pmcid">PMC1097763</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Arredondo Montero J, Pérez Riveros BP, Bronte Anaut M, et al. Ileal inflammatory myofibroblastic tumor in a two-month-old girl: long-term follow-up. Indian J Pediatr. 2022;89(12):1264. The immunohistochemistry results are as follows.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12098-022-04367-x</pub-id><pub-id pub-id-type="pmid">36217007</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mesaros</surname><given-names>EF</given-names></name><name name-style="western"><surname>Ott</surname><given-names>GR</given-names></name><name name-style="western"><surname>Dorsey</surname><given-names>BD</given-names></name></person-group><article-title>Anaplastic lymphoma kinase inhibitors as anticancer therapeutics : a patent review</article-title><source>Eeport Opin Ther Pat</source><year>2014</year><volume>24</volume><issue>4</issue><fpage>417</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1517/13543776.2014.877890</pub-id><pub-id pub-id-type="pmid">24476492</pub-id></element-citation></ref></ref-list></back></article>